Who Paid My Doc
A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation
ClinicalTrials.gov NCT03173248
Research payments
$243,088
Through program year 2019, $243,088 in research payments was reported against A Phase 3, Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of AG-120 in Combination with Azacitidine in Subjects 18 Years of Age with Previously Untreated Acute Myeloid Leukemia with an IDH1 Mutation, across 65 payments, paid by Agios Pharmaceuticals, Inc..
- Paid by
- Agios Pharmaceuticals, Inc.
- ClinicalTrials.gov
- NCT03173248
By program year
1 row| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2019 | Research | $243,088 | 65 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
10 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Darla Liles Greenville, NC Named on 9 payments
- Ashkan Emadi Baltimore, MD Named on 9 payments
- Jana Reynolds Dallas, TX Named on 8 payments
- Gail Roboz New York, NY Named on 5 payments
- Olatoyosi Odenike Burr Ridge, IL Named on 5 payments
- Gary Schiller Los Angeles, CA Named on 4 payments
- Abdul Hai Mansoor Portland, OR Named on 4 payments
- Michael Schuster New York, NY Named on 4 payments
- David Rizzieri Durham, NC Named on 3 payments
- Don Stevens Louisville, KY Named on 3 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.